Form 4: IDEAYA Biosciences Director Granted 20,000 Stock Options

Catherine J. Mackey, a Director at IDEAYA Biosciences, Inc., was granted 20,000 stock options with an exercise price of $21.78, aligning her interests with shareholder value.

Summary

• Catherine J. Mackey, a Director of IDEAYA Biosciences, Inc. (IDYA), was granted 20,000 stock options.
• The stock options have an exercise price of $21.78 per share.
• The grant date for these options was June 24, 2025.
• The options are set to expire on June 24, 2035.
• The vesting schedule for these options is 100% on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the Annual Meeting following the grant date, contingent on Ms. Mackey's continued service on the Board.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of director compensation. While not indicative of operational performance, the grant of options is generally viewed as a positive for aligning director and shareholder interests, hence a slightly positive sentiment.

Positives

• The grant of stock options to a director aligns their financial interests directly with the long-term performance and shareholder value of IDEAYA Biosciences, Inc.

Future Outlook

This filing is a disclosure of a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook, beyond the vesting schedule of the options.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation designed to align the interests of board members with those of shareholders. This practice is standard across publicly traded companies, particularly in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across the biotechnology and broader corporate landscape, consistent with global benchmarks for executive and board remuneration.
• The vesting schedule, which ties full vesting to either a one-year anniversary or the next annual meeting, is typical for director equity grants, aiming to retain talent and ensure continued board engagement.

Stakeholder Impact

• Shareholders: The grant of stock options to a director helps align the director's financial incentives with the long-term interests of shareholders, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The stock options will vest on the earlier of June 24, 2026 (first anniversary of grant) or immediately prior to the Annual Meeting following the grant date, subject to continued service.

Key Dates

Keywords

IDEAYA Biosciences, IDYA, SEC Form 4, Stock Option Grant, Director Compensation, Insider Transaction, Equity Incentive, Catherine J. Mackey